BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 9003111)

  • 1. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.
    González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M
    Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
    Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
    JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
    Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
    Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET proto-oncogene mutations in French MEN 2A and FMTC families.
    Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
    Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.
    Egawa S; Futami H; Takasaki K; Iihara M; Okamoto T; Kanbe M; Ohi T; Saio Y; Miyauchi A; Takiyama Y; Koga M; Miyanaga K; Inoue K; Mitsuyama S; Nomura Y; Takei H; Mugiya S; Ishida O; Zeze F; Shakutsui S; Inoue H; Oya H; Yoshimura A; Ishizuka S; Yamaguchi K
    Jpn J Clin Oncol; 1998 Oct; 28(10):590-6. PubMed ID: 9839497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
    Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
    Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
    Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
    Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.